SCHEMBL19911432

SCHEMBL19911432

O=C(n1cnc2cc(F)ccc21)C(F)(F)F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.46
GFER P55789 1/20 0.46
KCNMA1 Q12791 2/20 0.39
LMNA P02545 2/20 0.35
FGFR1 P11362 1/20 0.35
TSHR P16473 1/20 0.35
MAPK10 P53779 1/20 0.35
HSD17B10 Q99714 1/20 0.35
THRB P10828 1/20 0.35
SCN9A Q15858 1/20 0.35
ALDH1A1 P00352 2/20 0.35
HCAR1 Q9BXC0 1/20 0.35
HPGD P15428 1/20 0.34
MEN1 O00255 1/20 0.34
PRPS1 P60891 1/20 0.34
DPP4 P27487 1/20 0.34
DPP9 Q86TI2 1/20 0.34
DPP7 Q9UHL4 1/20 0.34
CYP3A4 P08684 1/20 0.34
IDO1 P14902 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19848123 0.88 KMT2A (0.46) KMT2AGFERHCAR1MEN1DPP4
SCHEMBL19848094 0.83 FGFR1 (0.44) KMT2AGFERKCNMA1LMNAFGFR1
SCHEMBL19848391 0.83 NPSR1 (0.48) KCNMA1LMNAMAPK10ALDH1A1HPGD
SCHEMBL19848142 0.83 MAPT (0.45) KMT2AGFERFGFR1HSD17B10ALDH1A1
SCHEMBL16822326 0.82 KMT2A (0.49) KMT2AGFERKCNMA1LMNAFGFR1
SCHEMBL19848406 0.81 KMT2A (0.51) KMT2AGFERKCNMA1LMNAFGFR1
SCHEMBL19848231 0.80 GABRP (0.40) KMT2AGFERALDH1A1IDO1KCNH2
SCHEMBL19911342 0.80 KMT2A (0.48) KMT2AFGFR1TSHRALDH1A1HPGD
SCHEMBL19848351 0.79 KMT2A (0.53) KMT2ALMNAHSD17B10ALDH1A1HPGD
SCHEMBL19911382 0.79 ALDH1A1 (0.51) KMT2ALMNAFGFR1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10756394-B2 Nonaqueous electrolyte and nonaqueous secondary battery ASAHI KASEI KABUSHIKI KAISHA (JP) 2020-08-25 US disclosed
EP-3467930-A1 NONAQUEOUS ELECTROLYTE AND NONAQUEOUS SECONDARY BATTERY ASAHI KASEI KABUSHIKI KAISHA (JP) 2019-04-10 EP disclosed
US-20180062213-A1 Nonaqueous Electrolyte and Nonaqueous Secondary Battery ASAHI KASEI KABUSHIKI KAISHA (JP) 2018-03-01 US disclosed
US-20180062213-A1 Nonaqueous Electrolyte and Nonaqueous Secondary Battery ASAHI KASEI KABUSHIKI KAISHA (JP) 2018-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10756394-B2 Nonaqueous electrolyte and nonaqueous secondary battery BPTF, BRD4, KCNN2 KMT2A 458/4885GFER 3037/4885KCNMA1 525/4885
US-20180062213-A1 Nonaqueous Electrolyte and Nonaqueous Secondary Battery BPTF, BRD4, KCNN2 KMT2A 458/4885GFER 3037/4885KCNMA1 525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.